Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inulin for MDRO prevention in critical illness
NCT03865706Phase 2Completed
- Sponsor
- Columbia University
- Start
- Oct 2019
- Primary completion
- Nov 2023
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of inulin in Infection and nosocomial infection (3 arms), sponsored by Columbia University. Primary endpoint: Within-individual Change in SCFA Producer Level at Day 3. Started Oct 2019; status: completed.
02
Drugs
inulin
03
Conditions
Infectionnosocomial infection
Beyond the preview
Go deeper on NCT03865706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865706.